Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of DTcP in Infants
NCT05951725Phase 3Active, not recruiting
- Sponsor
- CanSino Biologics Inc.
- Start
- Aug 2023
- Primary completion
- Apr 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of diphtheria + tetanus + acellular pertussis (3-component) in pertussis, diphtheria and Tetanus (6 arms), sponsored by CanSino Biologics Inc. Primary endpoints: Serum anti-PT, FHA, PRN, DT, TT antibody positive conversion rate, Geometric Mean Concentration and 1 more. Started Aug 2023; status: active, not recruiting.
02
Drugs
diphtheria + tetanus + acellular pertussis (3-component)
03
Conditions
pertussisdiphtheriaTetanus
Beyond the preview
Go deeper on NCT05951725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05951725.